<?xml version="1.0" encoding="UTF-8"?>
<p>mAb therapies have also been proposed for HIV. The case for HIV was recently reviewed [
 <xref rid="pntd.0007860.ref139" ref-type="bibr">139</xref>, 
 <xref rid="pntd.0007860.ref140" ref-type="bibr">140</xref>]. Two such mAbs are in Phase III trials: PRO 140 and Cenicriviroc. PRO 140 targets CCR5 (cysteine-cysteine chemokine receptor type 5) and recently entered Phase IIb/III trials for weekly subcutaneous dosing for monotherapy maintenance [
 <xref rid="pntd.0007860.ref141" ref-type="bibr">141</xref>]. Cenicriviroc is a dual CCR2 and CCR5 antagonist investigated for a number of indications, including HIV infection [
 <xref rid="pntd.0007860.ref142" ref-type="bibr">142</xref>]. As noted earlier, ibalizumab was recently approved as a second-line treatment for HIV treatment [
 <xref rid="pntd.0007860.ref013" ref-type="bibr">13</xref>].
</p>
